Vimarsana
Biggest News Aggregation in the World

Page 4 - Outcome Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Outcome Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Outcome Sciences Today - Breaking & Trending Today

Almost half of participants in B.C. COVID-19 self-isolation study broke the rules - Vimarsana News

Almost half of participants in B.C. COVID-19 self-isolation study broke the rules

A B.C. study looking into self-isolation through the COVID-19 pandemic has found almost half the participants broke the rules.

We must harness digital technology for 21st-century health care - Vimarsana News

We must harness digital technology for 21st-century health care

We must harness digital technology for 21st-century health care By Karimah Es Sabar. Published on Apr 8, 2021 4:16pm 'While digital health such as telemedicine doesn’t replace the value of face-to-face contact, disruptive technologies such as real-time, embedded monitoring tools will help health-care specialists track and monitor patients without needing to see them.' The federal government's COVID-19 Exposure Notification app for smartphones (Health Canada) “Hiding within those mounds of data is knowledge that could change the life of a patient, or change the world.” — Dr....

National study looks at COVID-19 risk among paramedics - Vimarsana News

National study looks at COVID-19 risk among paramedics

Study of 5,000 paramedics in B.C. and Ontario led by scientist at the University of B.C. to look at COVID risk while at work.

Source: canada.com
NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity - Vimarsana News

NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity

NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity NeonMind Biosciences Inc. (CSE: NEON) (" NeonMind"), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia whe...